Floatz logo

Etarfolatide

Bladder Cancer

Endocyteprotein_peptidePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

122 Active assets in the Bladder Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Etarfolatide is also rated in:

ovarian cancerDormant
B
Indicative ·
58 / 100
View asset →
lung adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →